No significant differences were found in the incidence rates of hypertension, proteinuria, and hand-foot syndrome following treatment with lenvatinib between the genotypes of CYP3A4/5 and ABC transporters (Table 4). This evidence concerns the gene CYP3A4 and Hand-foot syndrome.